Advertisement

Current Oncology Reports

, Volume 15, Issue 6, pp 533–540 | Cite as

Role of Aspirin in Cancer Prevention

  • Mangesh A. Thorat
  • Jack Cuzick
Cancer Prevention (J Cuzick, Section Editor)

Abstract

Since its first synthesis in 1897, several medicinal roles and mechanisms of action of aspirin have become apparent; the latest among these being its role in cancer prevention and treatment. A large body of evidence supports aspirin’s effect in reducing cancer incidence and cancer mortality, but duration of use needs to be at least 5 years. The beneficial effects are particularly large for colorectal, oesophageal and gastric cancers, with apparently smaller reductions for breast, prostate and lung cancer. The major harm is gastrointestinal bleeding, but serious sequelae are minimal at ages <70 years. It is very likely that use of prophylactic aspirin in the general population aged 50–70+ years will result in net overall benefit. Outstanding issues are: whether standard dose (~300 mg/day) can lead to greater net benefits than low dose (75–100 mg/day), the optimum duration of use, and appropriate ages for use in average-risk individuals.

Keywords

Aspirin Prevention Cancer Cardiovascular disease Myocardial infarction Stroke Peptic ulcer Gastrointestinal bleeding Benefit-harm Helicobacter pylori 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Mangesh A. Thorat declares no conflict of interest.

Jack Cuzick is a member of Bayer advisory board.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Mahdi JG, Mahdi AJ, Mahdi AJ, Bowen ID. The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif. 2006;39:147–55.PubMedCrossRefGoogle Scholar
  2. 2.
    Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000;321:1591–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Miner J, Hoffhines A. The discovery of aspirin's antithrombotic effects. Tex Heart Inst J. 2007;34:179–86.PubMedGoogle Scholar
  6. 6.
    Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10:501–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206–11.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhou G, Marathe GK, Willard B, McIntyre TM. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. J Biol Chem. 2011;286:34820–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science. 2001;293:1673–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fat Acids. 2005;73:141–62.CrossRefGoogle Scholar
  12. 12.
    Smith HS. Aspirin-inspired analgesia: old drug, new mechanism, Sans Cox? Pain Physician. 2012;15:E359–61.PubMedGoogle Scholar
  13. 13.
    McQuay HJ, Moore RA. Dose-response in direct comparisons of different doses of aspirin, ibuprofen and paracetamol (acetaminophen) in analgesic studies. Br J Clin Pharmacol. 2007;63:271–8.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012. This overview of a large number of RCTs confirmed the benefits of aspirin on cancer incidence and mortality, as reported in an earlier overview of selected RCTs with long-term follow-up. It also confirmed that it takes at least 3 years for the beneficial effects to become apparent. Google Scholar
  15. 15.
    •• Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376:1741–50. This expanded overview of RCTs confirmed the benefits of aspirin on colorectal cancer incidence and mortality, as reported in an earlier overview.PubMedCrossRefGoogle Scholar
  16. 16.
    •• Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012. This overview of a large number of RCTs demonstrated that aspirin use at the time of cancer diagnosis and / or after diagnosis results in reduction in the risk of cancer metastasis. Google Scholar
  17. 17.
    Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of Aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106:1564–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649–58.PubMedCrossRefGoogle Scholar
  19. 19.
    Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28:1467–72.PubMedCrossRefGoogle Scholar
  20. 20.
    McCowan C, Munro AJ, Donnan PT, Steele RJ. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Canc. 2013;49:1049–57.CrossRefGoogle Scholar
  21. 21.
    Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Canc Prev Res. 2012;5:164–78.CrossRefGoogle Scholar
  22. 22.
    Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252–66.PubMedCrossRefGoogle Scholar
  23. 23.
    Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131–42.PubMedCrossRefGoogle Scholar
  24. 24.
    •• Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31–41. This overview of RCTs with long-term follow-up demonstrated the effect of aspirin on overall cancer deaths. It showed that it takes at least 3 years for the beneficial effects to become apparent. It also demonstrated that benefits are largest with scheduled treatment duration of 7.5 years or more.Google Scholar
  25. 25.
    Hubner RA, Muir KR, Liu JF, et al. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Canc Res. 2008;14:2303–9.CrossRefGoogle Scholar
  26. 26.
    Din FV, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142:1504–15 e3.PubMedCrossRefGoogle Scholar
  27. 27.
    • Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science. 2012;336:918–22. This study reported a new mechanism of aspirin action through AMP-kinase pathway.PubMedCrossRefGoogle Scholar
  28. 28.
    • Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596–606. This study showed a large magnitude of aspirin benefits in colorectal cancer patients with PIK3CA mutation in their tumours. The finding of this study, if replicated, could help in personalising aspirin use in adjuvant treatment of colorectal cancer.PubMedCrossRefGoogle Scholar
  29. 29.
    Kaur J, Sanyal SN. PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac. Tumour Biol. 2010;31:623–31.PubMedCrossRefGoogle Scholar
  30. 30.
    Uddin S, Ahmed M, Hussain A, et al. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2010;126:382–94.PubMedCrossRefGoogle Scholar
  31. 31.
    Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem. 2006;281:29228–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Lu M, Strohecker A, Chen F, et al. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Canc Res. 2008;14:3168–76.CrossRefGoogle Scholar
  33. 33.
    Shaw RJ, Cantley LC. Cell biology. Ancient sensor for ancient drug. Science. 2012;336:813–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Gasic GJ, Gasic TB, Murphy S. Anti-metastatic effect of aspirin. Lancet. 1972;2:932–3.PubMedCrossRefGoogle Scholar
  35. 35.
    Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61:46–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012;9:259–67.PubMedCrossRefGoogle Scholar
  37. 37.
    Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology. 2008;134:21–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88:684–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256–66.PubMedCrossRefGoogle Scholar
  41. 41.
    • Burn J, Gerdes A-M, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081–7. This RCT in individuals at high risk of colorectal cancer showed a large benefit in aspirin users with just 2 years of scheduled treatment and in a relatively shorter follow-up time. High underlying risk and use of a larger aspirin dose (600 mg/day) could be the reasons for early benefit of large magnitude.PubMedCrossRefGoogle Scholar
  42. 42.
    •• Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012. This overview of a large number of RCTs and observational studies confirmed the benefits of aspirin on cancer. It also showed that the effects seen in RCTs and case-control studies are largely consistent. Google Scholar
  43. 43.
    •• Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23. This overview of a large number of observational studies demonstrated the benefits of aspirin on cancer incidence and mortality for several cancer sites. Authors also investigated effects of dose and duration separately for each site.Google Scholar
  44. 44.
    •• Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77–85. These long-term results of a large RCT (WHS) have conclusively demonstrated aspirin’s effect in reducing colorectal cancer incidence. It took 10 years for the beneficial effects to become apparent, but a large magnitude (42 %) of post-treatment benefit and an overall 20 % reduction is consistent with rest of the literature. Of particular importance is the fact that such large benefit was seen even when only 100 mg aspirin was taken on alternate days.Google Scholar
  45. 45.
    Rothwell PM. Alternate-day, low-dose aspirin and cancer risk. Ann Intern Med. 2013;159:148–50.PubMedCrossRefGoogle Scholar
  46. 46.
    Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562–72.PubMedCrossRefGoogle Scholar
  47. 47.
    • Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst. 2012;104:1208–17. These long-term results of a large cohort (CPS-II Nutrition cohort) have shown the beneficial effects of aspirin on reduction in cancer mortality.PubMedCrossRefGoogle Scholar
  48. 48.
    Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24:3177–84.PubMedGoogle Scholar
  49. 49.
    Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath Jr CW. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322–7.PubMedGoogle Scholar
  50. 50.
    Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer. 2011;128:2444–52.PubMedCrossRefGoogle Scholar
  51. 51.
    USPSTF. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146:361–4.CrossRefGoogle Scholar
  52. 52.
    USPSTF. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404.CrossRefGoogle Scholar
  53. 53.
    Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85:1220–4.PubMedCrossRefGoogle Scholar
  54. 54.
    Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med. 1998;128:713–20.PubMedCrossRefGoogle Scholar
  55. 55.
    Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294:47–55.PubMedCrossRefGoogle Scholar
  56. 56.
    Luo T, Yan HM, He P, Luo Y, Yang YF, Zheng H. Aspirin use and breast cancer risk: a meta-analysis. Breast Canc Res Treat. 2012;131:581–7.CrossRefGoogle Scholar
  57. 57.
    Jacobs EJ, Connell CJ, Rodriguez C, Patel AV, Calle EE, Thun MJ. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst. 2004;96:524–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105:1107–13.PubMedCrossRefGoogle Scholar
  59. 59.
    Ali R, Toh HC, Chia WK. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer–the ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011;12:261.PubMedCrossRefGoogle Scholar
  60. 60.
    Fontaine E, McShane J, Page R, et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg. 2010;38:21–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755–62.PubMedCrossRefGoogle Scholar
  62. 62.
    Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.PubMedCrossRefGoogle Scholar
  63. 63.
    Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. A prospective study of aspirin use and the risk of gastrointestinal bleeding in men. PLoS ONE. 2010;5:e15721.PubMedCrossRefGoogle Scholar
  65. 65.
    McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624–38.PubMedCrossRefGoogle Scholar
  66. 66.
    •• Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621–9. This overview of RCTs investigated aspirin-related bleeding harms, GI bleeding, major bleeding and haemorrhagic strokes.PubMedCrossRefGoogle Scholar
  67. 67.
    Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005;95:1218–22.PubMedCrossRefGoogle Scholar
  68. 68.
    Button LA, Roberts SE, Evans PA, et al. Hospitalized incidence and case fatality for upper gastrointestinal bleeding from 1999 to 2007: a record linkage study. Aliment Pharmacol Ther. 2010;33:64–76.CrossRefGoogle Scholar
  69. 69.
    Hasselgren G, Blomqvist A, Eriksson S, Henningsson A, Lundell L. Short and long term course of elderly patients with peptic ulcer bleeding–analysis of factors influencing fatal outcome. Eur J Surg. 1998;164:685–91.PubMedCrossRefGoogle Scholar
  70. 70.
    Henry DA, Johnston A, Dobson A, Duggan J. Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids. Br Med J (Clin Res Ed). 1987;295:1227–9.CrossRefGoogle Scholar
  71. 71.
    Kang JY, Elders A, Majeed A, Maxwell JD, Bardhan KD. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther. 2006;24:65–79.PubMedCrossRefGoogle Scholar
  72. 72.
    Paspatis GA, Matrella E, Kapsoritakis A, et al. An epidemiological study of acute upper gastrointestinal bleeding in Crete, Greece. Eur J Gastroenterol Hepatol. 2000;12:1215–20.PubMedCrossRefGoogle Scholar
  73. 73.
    Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633–41.PubMedCrossRefGoogle Scholar
  74. 74.
    Garcia Rodriguez LA, Ruigomez A, Hasselgren G, Wallander MA, Johansson S. Comparison of mortality from peptic ulcer bleed between patients with or without peptic ulcer antecedents. Epidemiology. 1998;9:452–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.PubMedCrossRefGoogle Scholar
  76. 76.
    Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol. 2006;4:130–42.PubMedCrossRefGoogle Scholar
  77. 77.
    Jackson L, Britton J, Lewis SA, et al. A population-based epidemiologic study of Helicobacter pylori infection and its association with systemic inflammation. Helicobacter. 2009;14:108–13.PubMedCrossRefGoogle Scholar
  78. 78.
    Vyse AJ, Gay NJ, Hesketh LM, et al. The burden of Helicobacter pylori infection in England and Wales. Epidemiol Infect. 2002;128:411–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet. 2002;359:9–13.PubMedCrossRefGoogle Scholar
  81. 81.
    Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996;348:150–4.PubMedCrossRefGoogle Scholar
  82. 82.
    Roderick P, Davies R, Raftery J, et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess. 2003;7:1–86.PubMedGoogle Scholar
  83. 83.
    Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–71.PubMedCrossRefGoogle Scholar
  84. 84.
    Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1–9.PubMedCrossRefGoogle Scholar
  85. 85.
    CancerStats—Cancer Statistics for the UK. 2011. Available at http://info.cancerresearchuk.org/cancerstats/. Accessed 25/04/2011.
  86. 86.
    Nelson M, Reid C, Beilin L, et al. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging. 2003;20:897–903.PubMedCrossRefGoogle Scholar
  87. 87.
    Nelson MR, Reid CM, Ames DA, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust. 2008;189:105–9.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Centre for Cancer Prevention, Wolfson Institute of Preventive MedicineQueen Mary University of LondonLondonUK

Personalised recommendations